BACKGROUND AND OBJECTIVES: The development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) for B-lineage acute lymphoblastic leukemia (B-ALL) is associated with a lower probability of leukemia relapse. However, mechanisms by which this GVHD-associated graft-versus-leukemia effect is exerted are poorly understood. In this study, we simultaneously traced the kinetics of normal donor-derived and leukemic recipient-derived B-lymphopoiesis comparing patients with or without GVHD. DESIGN AND METHODS: We used multiparameter flow-cytometry to quantify pro-B (CD19+CD10+CD34+), pre-B (CD19+CD10+CD34-) precursors and malignant lymphoblasts identified by leukemia-associated markers in 161 prospective marrow samples from 39 consecutive B-ALL patients after allogeneic SCT. Chimerism analysis was performed by quantitative real-time polymerase chain reaction of null alleles and insertion/deletion (indel) polymorphisms. RESULTS: Acute GVHD of grades II-IV is associated with a strong inhibition of normal donor-derived pro-B and pre-B precursors at days +30 and +60 post-SCT. Patients who develop chronic GVHD have lower percentages of marrow B-cell precursors during the first year after SCT. Likewise, recipient-derived leukemia B cells were absent at days +30 and +60 in patients with acute GVHD grades II-IV and were less likely to be detected in patients with chronic GVHD. Induction of GVHD as treatment of increasing amounts of leukemia cells causes inhibition of both normal and malignant B compartments even in the absence of steroid therapy. INTERPRETATION AND CONCLUSIONS: We conclude that the development of GVHD after allogeneic SCT is associated with a non-specific inhibition of B-lymphopoiesis.
BACKGROUND AND OBJECTIVES: The development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) for B-lineage acute lymphoblastic leukemia (B-ALL) is associated with a lower probability of leukemia relapse. However, mechanisms by which this GVHD-associated graft-versus-leukemia effect is exerted are poorly understood. In this study, we simultaneously traced the kinetics of normal donor-derived and leukemic recipient-derived B-lymphopoiesis comparing patients with or without GVHD. DESIGN AND METHODS: We used multiparameter flow-cytometry to quantify pro-B (CD19+CD10+CD34+), pre-B (CD19+CD10+CD34-) precursors and malignant lymphoblasts identified by leukemia-associated markers in 161 prospective marrow samples from 39 consecutive B-ALL patients after allogeneic SCT. Chimerism analysis was performed by quantitative real-time polymerase chain reaction of null alleles and insertion/deletion (indel) polymorphisms. RESULTS: Acute GVHD of grades II-IV is associated with a strong inhibition of normal donor-derived pro-B and pre-B precursors at days +30 and +60 post-SCT. Patients who develop chronic GVHD have lower percentages of marrow B-cell precursors during the first year after SCT. Likewise, recipient-derived leukemia B cells were absent at days +30 and +60 in patients with acute GVHD grades II-IV and were less likely to be detected in patients with chronic GVHD. Induction of GVHD as treatment of increasing amounts of leukemia cells causes inhibition of both normal and malignant B compartments even in the absence of steroid therapy. INTERPRETATION AND CONCLUSIONS: We conclude that the development of GVHD after allogeneic SCT is associated with a non-specific inhibition of B-lymphopoiesis.
Authors: Raphael Itzykson; Marie Robin; Helene Moins-Teisserenc; Marc Delord; Marc Busson; Aliénor Xhaard; Flore Sicre de Fontebrune; Régis Peffault de Latour; Antoine Toubert; Gérard Socié Journal: Haematologica Date: 2014-09-26 Impact factor: 9.941
Authors: Yuri Fedoriw; T Danielle Samulski; Allison M Deal; Cherie H Dunphy; Andrew Sharf; Thomas C Shea; Jonathan S Serody; Stefanie Sarantopoulos Journal: Biol Blood Marrow Transplant Date: 2012-03-20 Impact factor: 5.742
Authors: Mark Bosch; Manveer Dhadda; Mette Hoegh-Petersen; Yiping Liu; Laura M Hagel; Peter Podgorny; Alejandra Ugarte-Torres; Faisal M Khan; Joanne Luider; Iwona Auer-Grzesiak; Adnan Mansoor; James A Russell; Andrew Daly; Douglas A Stewart; David Maloney; Michael Boeckh; Jan Storek Journal: Cytotherapy Date: 2012-09-18 Impact factor: 5.414
Authors: Steven D Schutt; Yongxia Wu; Chih-Hang Anthony Tang; David Bastian; Hung Nguyen; M Hanief Sofi; MengMeng Zhang; Chen Liu; Kris Helke; Carole Wilson; Lynn M Schnapp; Juan R Del Valle; Chih-Chi Andrew Hu; Xue-Zhong Yu Journal: Blood Adv Date: 2018-02-27
Authors: B C Beaudette-Zlatanova; P T Le; K L Knight; S Zhang; S Zakrzewski; M Parthasarathy; P J Stiff Journal: Bone Marrow Transplant Date: 2012-06-25 Impact factor: 5.483
Authors: Ahmad Khoder; Abdullah Alsuliman; Rafet Basar; Catherine Sobieski; Kayo Kondo; Amin Majid Alousi; Richard Szydlo; Muharrem Muftuoglu; Hila Shaim; Jane F Apperley; Elif Gokdemir; Nichola Cooper; Rohtesh S Mehta; David Marin; Richard Champlin; Elizabeth Shpall; Katayoun Rezvani Journal: Front Immunol Date: 2018-01-12 Impact factor: 7.561